ONCOMEDICS
Oncomedics is a biotechnology company that specializes in the research of personalized treatments against cancer, and the development of a system of diagnosis customized to individual treatment. The company also operates as a contract research organization that offers specialized services in the evaluation of novel anti-tumor agents during pre-clinical and clinical screening. In addition, it conducts internal research and development programs focusing on the development of the oncogramme, a new ... predictive assay in order to perform individualized therapy against cancer; and works on various ex vivo tumor cell types in order to help clinical and pharmaceutical anti-cancer researches, such as breast, colon, ovarian, and prostatic cancers. The company was founded in 2006 and is based in Limoges, France.
ONCOMEDICS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2006-01-01
Address:
Limoges, Limousin, France
Country:
France
Website Url:
http://www.oncomedics.com
Total Employee:
1+
Status:
Active
Contact:
33 5 55 33 85 25
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API WordPress Mobile Non Scaleable Content Sitelinks Search Box Yoast WordPress SEO Plugin Google Maps Yoast SEO Premium Yoast Plugins
Similar Organizations
Losan Pharma
Losan Pharma is a pharma-technology company that specializes in developing and manufacturing medicinal products.
Investors List
Limousin Business Angels
Limousin Business Angels investment in Angel Round - Oncomedics
Official Site Inspections
http://www.oncomedics.com
- Host name: clinifr7.peel.fr
- IP address: 87.98.174.171
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "Oncomedics"
Company profile - Oncomedics
Co-founder of Oncomedics SAS, Stéphanie Giraud has been involved in the project since 2004, mainly on its technical aspects. She holds a PhD from the University of Limoges in Biology …See details»
Oncomedics - Crunchbase Company Profile & Funding
Oncomedics is a biotechnology company that specializes in the research of personalized treatments against cancer, and the development of a system of diagnosis customized to …See details»
Oncomedics
5 rue Gemini 87068 - France Tel.: +33 5 55 33 85 25 Fax: +33 9 77 40 10 11 Email: [email protected]See details»
Oncomedics - LinkedIn
Oncomedics is a biotechnology company, part of CliniSciences Group, specializing in the personalization of cancer treatments. We are developing in vitro diagnostic medical devices …See details»
Oncomedics - IMODI Cancer
Oncomedics is a french company founded in 2006 for personalized cancer care. Oncomedics has developed a theranostic technology: the Oncogramme, based on human primary cell cultures …See details»
Oncomedics Company Profile 2024: Valuation, Funding …
Oncomedics General Information Description. Provider of biotechnology research services intended to make targeted chemotherapy for each patient in order to increase its effectiveness. The company's services predicts the effect of a …See details»
Oncomedics Company Profile - Office Locations, Competitors
Oncomedics is a biotechnology company that specializes in the research of personalized treatments against cancer. It collects human cancer tumor from patients to obtain cancer …See details»
Oncomedics - Funding, Financials, Valuation & Investors
Nov 29, 2017 Oncomedics is a biotechnology company that specializes in the research of personalized treatments against cancer. Search Crunchbase. Start Free Trial . Chrome …See details»
ALLIS-NA • Oncomedics
Oncomedics has designed and sells the Oncogramme®, a CE-marked medical device for the personalization of treatments. He predicts the effectiveness of chemotherapy before giving it to …See details»
Press release : Oncomedics joins CliniSciences Group
Oncomedics is a biotechnology company specialising in the personalisation of cancer treatments. It develops in vitro diagnostic medical devices that provide practitioners (surgeons, …See details»
Oncomedics joins CliniSciences Group
Oncomedics is a biotechnology company specialising in the personalisation of cancer treatments. It develops in vitro diagnostic medical devices that provide practitioners (surgeons, …See details»
Oncomedics FOCUS: Personnalizing the cancer treatments
Nov 9, 2016 Oncomedics is a biotechnology company specialised in the individualisation of cancer treatments: it develops diagnosis tools to personalize anti-cancer cures, thereby …See details»
Oncomedics - CliniSciences
Oncomedics is a biotechnology company specialising in the personalisation of cancer treatments. We are developing in vitro diagnostic medical devices that provide decision support to …See details»
Oncomedics
Co-founder of Oncomedics SAS, Stéphanie Giraud has been involved in the project since 2004, mainly on its technical aspects. She holds a PhD from the University of Limoges in Biology …See details»
Oncomedics - OncoSTART
Oncomedics created the Oncogramme®: it is an in vitro medical device that allows identifying the most appropriate drug/drug combination to target the patient’s cancer cells. The …See details»
Oncomedics
Oncomedics is a biotechnology company specialising in the personalisation of cancer treatments. We are developing in vitro diagnostic medical devices that provide decision support to …See details»
OncoTRIP Bioassays - IMODI Cancer
OncoTRIP Bioassays. Today, Oncomedics is a service company dedicated to support scientific breakthroughs in the treatment of cancer. Based on our expertise, Oncomedics has developed …See details»
Oncomedics
ESTER Technopôle, 1 avenue d'Ester 87069 Limoges - France Tel.: +33 5 55 33 85 25 Fax: +33 9 77 40 10 11 Email: [email protected]See details»
[Partnership] For personalised treatment in oncology
Feb 8, 2023 Eurofins Biomnis has joined forces with the French biotechnology company Oncomedics, an expert in personalised cancer treatment. This partnership enable Eurofins …See details»
Oncogramme®: Towards personalised medicine for all cancer
In December 2019, Oncomedics received a favourable decision from the French National Authority for Health (HAS) via the “Forfait Innovation” for the derogatory reimbursement of the …See details»